BRAF and metastatic neoplasm: Uncountable phase III clinical trials, evaluating the combination of dabrafenib and trametinib in previously untreated melanoma patients with unresectable or metastatic disease harboring a BRAF V600E or V600K mutation, showed the improvement in PFS and OS compared with conventional chemotherapy or placebo, establishing the combined therapy as a standard treatment in melanoma harboring BRAF Val 600 mutations [99–101].